vs
Side-by-side financial comparison of ARGENX SE (ARGX) and Teradyne (TER). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $1.3B, roughly 1.9× Teradyne). ARGENX SE runs the higher net margin — 35.5% vs 31.1%, a 4.4% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs 83.2%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.
ARGX vs TER — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $1.3B |
| Net Profit | $877.2M | $398.9M |
| Gross Margin | 89.5% | 60.9% |
| Operating Margin | 28.9% | 36.9% |
| Net Margin | 35.5% | 31.1% |
| Revenue YoY | 83.2% | 87.0% |
| Net Profit YoY | 1.3% | — |
| EPS (diluted) | $13.25 | $2.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $2.5B | $1.1B | ||
| Q3 25 | — | $769.2M | ||
| Q2 25 | $1.8B | $651.8M | ||
| Q1 25 | — | $685.7M | ||
| Q4 24 | $1.4B | $752.9M | ||
| Q3 24 | — | $737.3M | ||
| Q2 24 | $901.9M | $729.9M |
| Q1 26 | — | $398.9M | ||
| Q4 25 | $877.2M | $257.2M | ||
| Q3 25 | — | $119.6M | ||
| Q2 25 | $414.8M | $78.4M | ||
| Q1 25 | — | $98.9M | ||
| Q4 24 | $865.6M | $146.3M | ||
| Q3 24 | — | $145.6M | ||
| Q2 24 | $-32.5M | $186.3M |
| Q1 26 | — | 60.9% | ||
| Q4 25 | 89.5% | 57.2% | ||
| Q3 25 | — | 58.4% | ||
| Q2 25 | 89.2% | 57.2% | ||
| Q1 25 | — | 60.6% | ||
| Q4 24 | 90.2% | 59.4% | ||
| Q3 24 | — | 59.2% | ||
| Q2 24 | 89.4% | 58.3% |
| Q1 26 | — | 36.9% | ||
| Q4 25 | 28.9% | 27.1% | ||
| Q3 25 | — | 18.9% | ||
| Q2 25 | 19.2% | 13.9% | ||
| Q1 25 | — | 17.6% | ||
| Q4 24 | 8.7% | 20.4% | ||
| Q3 24 | — | 20.6% | ||
| Q2 24 | -15.4% | 28.8% |
| Q1 26 | — | 31.1% | ||
| Q4 25 | 35.5% | 23.7% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | 23.4% | 12.0% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | 64.1% | 19.4% | ||
| Q3 24 | — | 19.8% | ||
| Q2 24 | -3.6% | 25.5% |
| Q1 26 | — | $2.53 | ||
| Q4 25 | $13.25 | $1.62 | ||
| Q3 25 | — | $0.75 | ||
| Q2 25 | $6.32 | $0.49 | ||
| Q1 25 | — | $0.61 | ||
| Q4 24 | $13.33 | $0.89 | ||
| Q3 24 | — | $0.89 | ||
| Q2 24 | $-0.55 | $1.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | $241.9M |
| Total DebtLower is stronger | — | $0 |
| Stockholders' EquityBook value | $7.3B | — |
| Total Assets | $8.7B | $4.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $241.9M | ||
| Q4 25 | $3.5B | $293.8M | ||
| Q3 25 | — | $272.7M | ||
| Q2 25 | $2.1B | $339.3M | ||
| Q1 25 | — | $475.6M | ||
| Q4 24 | $1.5B | $553.4M | ||
| Q3 24 | — | $510.0M | ||
| Q2 24 | $1.4B | $421.9M |
| Q1 26 | — | $0 | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $11.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $7.3B | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $6.1B | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | $5.5B | $2.8B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | $4.3B | $2.7B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $8.7B | $4.2B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $7.2B | $3.8B | ||
| Q1 25 | — | $3.7B | ||
| Q4 24 | $6.2B | $3.7B | ||
| Q3 24 | — | $3.8B | ||
| Q2 24 | $4.8B | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | $265.1M |
| Free Cash FlowOCF − Capex | $322.4M | — |
| FCF MarginFCF / Revenue | 13.0% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 0.37× | 0.66× |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $265.1M | ||
| Q4 25 | $323.3M | $281.6M | ||
| Q3 25 | — | $49.0M | ||
| Q2 25 | $361.8M | $182.1M | ||
| Q1 25 | — | $161.6M | ||
| Q4 24 | $41.9M | $282.6M | ||
| Q3 24 | — | $166.3M | ||
| Q2 24 | $-124.7M | $216.1M |
| Q1 26 | — | — | ||
| Q4 25 | $322.4M | $218.8M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $356.6M | $131.7M | ||
| Q1 25 | — | $97.6M | ||
| Q4 24 | $40.9M | $225.2M | ||
| Q3 24 | — | $114.4M | ||
| Q2 24 | $-125.5M | $171.2M |
| Q1 26 | — | — | ||
| Q4 25 | 13.0% | 20.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 20.1% | 20.2% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | 3.0% | 29.9% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | -13.9% | 23.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.8% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | 0.3% | 7.7% | ||
| Q1 25 | — | 9.3% | ||
| Q4 24 | 0.1% | 7.6% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | 0.1% | 6.1% |
| Q1 26 | — | 0.66× | ||
| Q4 25 | 0.37× | 1.09× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | 0.87× | 2.32× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | 0.05× | 1.93× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
